HomeInsightsStock Comparison

Biocon Ltd vs Wockhardt Ltd Stock Comparison

Biocon Ltd vs Wockhardt Ltd Stock Comparison

Last Updated on: Jun 05, 2025

Key Highlights

  • The Latest Trading Price of Biocon Ltd is ₹ 330.65 as of 05 Jun 15:30.
  • The P/E Ratio of Biocon Ltd changed from 43.4 on March 2020 to 31 on March 2024 . This represents a CAGR of -6.51% over 5 yearsThe P/E Ratio of Wockhardt Ltd changed from 6.6 on March 2021 to 0 on March 2024 . This represents a CAGR of -100.00% over 4 years.
  • The Market Cap of Biocon Ltd changed from ₹ 32472 crore on March 2020 to ₹ 31707 crore on March 2024 . This represents a CAGR of -0.48% over 5 yearsThe Market Cap of Wockhardt Ltd changed from ₹ 1912 crore on March 2020 to ₹ 8951 crore on March 2024 . This represents a CAGR of 36.16% over 5 years.
  • The revenue of Biocon Ltd for the Mar '25 is ₹ 4474 crore as compare to the Dec '24 revenue of ₹ 3874 crore. This represent the growth of 15.49% The revenue of Wockhardt Ltd for the Mar '25 is ₹ 758 crore as compare to the Dec '24 revenue of ₹ 729 crore. This represent the growth of 3.98%.
  • The ebitda of Biocon Ltd for the Mar '25 is ₹ 1135 crore as compare to the Dec '24 ebitda of ₹ 804.7 crore. This represent the growth of 41.11% The ebitda of Wockhardt Ltd for the Mar '25 is ₹ 79 crore as compare to the Dec '24 ebitda of ₹ 136 crore. This represent the decline of -41.91%.
  • The net profit of Biocon Ltd changed from ₹ 148.9 crore to ₹ 459.4 crore over 8 quarters. This represents a CAGR of 75.65% The net profit of Wockhardt Ltd changed from ₹ -136 crore to ₹ -45 crore over 8 quarters. This represents a CAGR of -42.48% .
  • The Dividend Payout of Biocon Ltd changed from 69.72 % on March 2022 to 50.32 % on March 2024 . This represents a CAGR of -10.30% over 3 yearsThe Dividend Payout of Wockhardt Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Biocon Ltd

  • Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company.
  • Biocon, with its key business verticals of Generics, Biosimilars, Research Services and Novel Biologics, has leveraged its affordable innovation model and scientific capabilities to develop and manufacture both small and large molecules at global scale for the benefit of patients.
  • At present, Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw.
  • Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind.
  • In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International.

About Wockhardt Ltd

  • Wockhardt Limited, incorporated in July, 1999 is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world.
  • The Company is India's leading research-based global healthcare enterprise in fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals.
  • It has 12 manufacturing locations and there are 3 locations where research and development activities are carried out. The Company has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland.
  • It has a significant presence in USA, Europe and India, with 83% of its global revenues coming from international businesses.
  • Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified lnfectious Diseases Programme) for 5 of Anti-bacterial discovery programmes - 2 of them are Gram Negative and 3 Gram Positive effective against untreatable 'Superbugs'.

Biocon Ltd News Hub

News

Biocon gets CDSCO approval for Liraglutide drug substance

Additionally, its wholly owned subsidiary, Biocon Pharma, has received CDSCO approval for ...

Read more

03 Jun 2025 08:23

News

Biocon Ltd spurts 1.3%, up for five straight sessions

Biocon Ltd rose for a fifth straight session today. The stock is quoting at Rs 343.8, up 1...

Read more

19 May 2025 13:00

News

Biocon's subsidiary get US FDA nod for anticoagulant medication Rivaroxaban

Rivaroxaban is a prescription medication used in the treatment of deep vein thrombosis and...

Read more

16 May 2025 09:38

News

Board of Biocon recommends final dividend

Biocon announced that the Board of Directors of the Company at its meeting held on 8 May 2...

Read more

09 May 2025 09:23

News

Biocon to hold AGM

Biocon announced that the 47th Annual General Meeting(AGM) of the company will be held on ...

Read more

09 May 2025 09:23

News

Biocon edges higher after biologics arm secures multiple market access deals for Yesintek

These agreements include key placements on national and regional formularies. Express Scri...

Read more

05 May 2025 09:31

Wockhardt Ltd News Hub

News

Wockhardt to conduct board meeting

Wockhardt will hold a meeting of the Board of Directors of the Company on 29 May 2025. Pow...

Read more

24 May 2025 18:26

News

Wockhardt announces incorporation of step-down subsidiary in Ireland

Wockhardt Bio AG, a subsidiary of Wockhardt, has incorporated a new Wholly Owned Subsidiar...

Read more

08 Apr 2025 19:55

News

Wockhardt surges after breakthrough US cancer treatment with Zaynich

The 15-year-old patient, diagnosed with Acute Myeloid Leukemia (AML), had been battling a ...

Read more

01 Apr 2025 11:32

News

Wockhardt announces board meeting date

Wockhardt will hold a meeting of the Board of Directors of the Company on 7 February 2025....

Read more

03 Feb 2025 16:52

News

Wockhardt spurts after Indian drug regulator approves Pneumonia antibiotic

Miqnaf is an ultra-short course, once-a-day, 3-day treatment for CABP, including those cau...

Read more

03 Jan 2025 11:22

News

Wockhardt to conduct board meeting

Wockhardt will hold a meeting of the Board of Directors of the Company on 13 November 2024...

Read more

08 Nov 2024 16:42

SWOT Analysis Of Biocon Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Wockhardt Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Biocon Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Wockhardt Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Biocon Ltd and Wockhardt Ltd

Which company has a larger market capitalization, Biocon Ltd or Wockhardt Ltd?

Market cap of Biocon Ltd is 39,697 Cr while Market cap of Wockhardt Ltd is 24,837 Cr

What are the key factors driving the stock performance of Biocon Ltd and Wockhardt Ltd?

The stock performance of Biocon Ltd and Wockhardt Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Biocon Ltd and Wockhardt Ltd?

As of June 5, 2025, the Biocon Ltd stock price is INR ₹330.65. On the other hand, Wockhardt Ltd stock price is INR ₹1528.6.

How do dividend payouts of Biocon Ltd and Wockhardt Ltd compare?

To compare the dividend payouts of Biocon Ltd and Wockhardt Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions